目的:探讨上皮性卵巢癌术后,化疗后CA125的最低水平与卵巢癌生物化学无进展时间以及预后的关系。方法:收集2000年1月～2002年12月在中山大学肿瘤防治中心妇科初治的经术后病理检查确诊的上皮性卵巢癌69例,其中Ⅰ组29例(化疗后CA125的最...目的:探讨上皮性卵巢癌术后,化疗后CA125的最低水平与卵巢癌生物化学无进展时间以及预后的关系。方法:收集2000年1月～2002年12月在中山大学肿瘤防治中心妇科初治的经术后病理检查确诊的上皮性卵巢癌69例,其中Ⅰ组29例(化疗后CA125的最低水平≤10U/mL)、Ⅱ组29例(10U/mL<化疗后CA125的最低水平≤20U/mL)、Ⅲ组11例(20U/mL<化疗后CA125的最低水平≤35U/mL),回顾性分析和比较不同CA125的水平患者的肿瘤生物化学无进展时间(free time to biochemical progression)及预后。用Kaplan-Meier法对其进行单因素分析,用Cox模型进行多因素分析。结果:Ⅰ、Ⅱ、Ⅲ组的中位生物化学无进展时间分别为49、30、8个月,三组之间的差异有统计学意义(P=0.002)。Ⅰ、Ⅱ、Ⅲ组的5年生存率分别为72.5%、59.6%、20.8%,三组之间的差异有统计学意义(P=0.001)。单因素分析结果显示,年龄、第3周期化疗前后的CA125水平、术后分期、CA125的最低水平是生物化学无进展时间及预后的影响因素(P<0.05)。Cox多因素回归分析结果显示,CA125的最低水平和术后分期是上皮性卵巢癌最为重要的独立预后因素。结论:CA125的最低水平是上皮性卵巢癌治疗效果监测的重要指标。展开更多
目的分析中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)和血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)对初诊多发性骨髓瘤(multiple myeloma,MM)患者总生存时间和无进展生存时间的影响。方法回顾性分析2...目的分析中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)和血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)对初诊多发性骨髓瘤(multiple myeloma,MM)患者总生存时间和无进展生存时间的影响。方法回顾性分析2015年1月-2018年8月临沂市人民医院血液科收治的128例MM患者临床资料。将MM患者分为低NLR组(NLR <2.444)和高NLR组(NLR≥2.444),低PLR组(PLR <145.234)和高PLR组(PLR≥145.234)。分析比较患者临床资料与总生存时间和无进展生存时间的关系。结果高NLR组48例,低NLR组80例。高NLR组患者肌酐、血清钙、β2-MG指标显著高于低NLR组(P均<0.05)。高PLR组41例,低PLR组87例。高PLR组患者血清白蛋白、β2-MG指标显著高于低PLR组(P均<0.05)。单因素分析显示,血清钙、血肌酐、血清白蛋白、β2-MG、NLR、PLR与总生存时间有关,β2-MG、NLR、PLR与无进展生存时间有关。多因素分析显示,NLR是MM患者无进展生存时间的独立预后因素(HR:0.444,95%CI:0.200～0.986)。结论初诊多发性骨髓瘤患者的NLR可作为无进展生存时间的独立预后因素,NLR较高预示着较短的无进展生存时间。展开更多
目的:探究NLR、LMR、PLR、D-D与接受免疫治疗的晚期非小细胞肺癌患者的无进展生存期的相关性。方法:回顾性分析接受免疫治疗的86例患者的临床资料,收集患者首次治疗前一周内的血常规及血清D-D,计算出NLR、LMR、PLR指标,根据RECIST1.1标...目的:探究NLR、LMR、PLR、D-D与接受免疫治疗的晚期非小细胞肺癌患者的无进展生存期的相关性。方法:回顾性分析接受免疫治疗的86例患者的临床资料,收集患者首次治疗前一周内的血常规及血清D-D,计算出NLR、LMR、PLR指标,根据RECIST1.1标准评价疗效并随访无进展生存期(progression-free survival, PFS),使用COX比例风险回归模型进行生存分析,筛选治疗前的基线参数中与疗效相关的指标。采用Kaplan⁃Meier法绘制生存曲线,用Log⁃rank检验比较组间生存率。探讨接受免疫治疗NSCLC患者PFS的影响因素。结果:通过预测非小细胞肺癌患者死亡率的ROC曲线分析确定,NLR最佳临界值为3.985,LMR最佳临界值为2.085,PLR最佳临界值为139.5,D-D最佳临界值为0.96。经过Log-rank检验得出单因素分析结果显示:性别、基因突变状态、器官转移个数、LMR、NLR、PLR及D-D是PFS的影响因素(p 0.05)。结论:在接受免疫治疗的NSCLC患者中,较低水平的NLR、PLR、D-D及较高水平的LMR患者与PFS更长相关,对其预后有一定的预测作用,基因突变状态、NLR、D-D是接受免疫治疗晚期NSCLC患者生存的独立预测因素。Objective: To explore the correlation between NLR, LMR, PLR, D-D and progression free survival in advanced non-small cell lung cancer patients receiving immunotherapy. Method: A retrospective analysis was conducted on the clinical data of 86 patients receiving immunotherapy. Blood routine and serum D-D were collected within one week before the first treatment, and NLR, LMR, and PLR indicators were calculated. The efficacy was evaluated according to the RECIST 1.1 standard and progression free survival (PFS) was followed up. The COX proportional hazards regression model was used for survival analysis, and indicators related to efficacy were screened from baseline parameters before treatment. Kaplan Meier method was used to plot survival curves, and Log rank test was used to compare survival rates between groups, exploring the influencing factors of PFS in NSCLC patients receiving immunotherapy. Result: Of ROC curve analysis for predicting the mortality rate of non-small cell lung cancer patients, the optimal critical values for NLR, LMR, PLR, and D-D were determined to be 3.985, 2.085, 139.5, and 0.96, respectively. After log rank testing, the results of univariate analysis showed that gender, gene mutation status, number of organ metastases, LMR, NLR, PLR, and D-D were the influencing factors of PFS (p 0.05). Conclusion: In NSCLC patients receiving immunotherapy, lower levels of NLR, PLR, D-D, and higher levels of LMR are associated with longer PFS and have a certain predictive effect on their prognosis. Gene mutation status, NLR, D-D are independent predictors of survival in advanced NSCLC patients receiving immunotherapy.展开更多
文摘目的:探讨上皮性卵巢癌术后,化疗后CA125的最低水平与卵巢癌生物化学无进展时间以及预后的关系。方法:收集2000年1月～2002年12月在中山大学肿瘤防治中心妇科初治的经术后病理检查确诊的上皮性卵巢癌69例,其中Ⅰ组29例(化疗后CA125的最低水平≤10U/mL)、Ⅱ组29例(10U/mL<化疗后CA125的最低水平≤20U/mL)、Ⅲ组11例(20U/mL<化疗后CA125的最低水平≤35U/mL),回顾性分析和比较不同CA125的水平患者的肿瘤生物化学无进展时间(free time to biochemical progression)及预后。用Kaplan-Meier法对其进行单因素分析,用Cox模型进行多因素分析。结果:Ⅰ、Ⅱ、Ⅲ组的中位生物化学无进展时间分别为49、30、8个月,三组之间的差异有统计学意义(P=0.002)。Ⅰ、Ⅱ、Ⅲ组的5年生存率分别为72.5%、59.6%、20.8%,三组之间的差异有统计学意义(P=0.001)。单因素分析结果显示,年龄、第3周期化疗前后的CA125水平、术后分期、CA125的最低水平是生物化学无进展时间及预后的影响因素(P<0.05)。Cox多因素回归分析结果显示,CA125的最低水平和术后分期是上皮性卵巢癌最为重要的独立预后因素。结论:CA125的最低水平是上皮性卵巢癌治疗效果监测的重要指标。
文摘目的分析中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)和血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)对初诊多发性骨髓瘤(multiple myeloma,MM)患者总生存时间和无进展生存时间的影响。方法回顾性分析2015年1月-2018年8月临沂市人民医院血液科收治的128例MM患者临床资料。将MM患者分为低NLR组(NLR <2.444)和高NLR组(NLR≥2.444),低PLR组(PLR <145.234)和高PLR组(PLR≥145.234)。分析比较患者临床资料与总生存时间和无进展生存时间的关系。结果高NLR组48例,低NLR组80例。高NLR组患者肌酐、血清钙、β2-MG指标显著高于低NLR组(P均<0.05)。高PLR组41例,低PLR组87例。高PLR组患者血清白蛋白、β2-MG指标显著高于低PLR组(P均<0.05)。单因素分析显示,血清钙、血肌酐、血清白蛋白、β2-MG、NLR、PLR与总生存时间有关,β2-MG、NLR、PLR与无进展生存时间有关。多因素分析显示,NLR是MM患者无进展生存时间的独立预后因素(HR:0.444,95%CI:0.200～0.986)。结论初诊多发性骨髓瘤患者的NLR可作为无进展生存时间的独立预后因素,NLR较高预示着较短的无进展生存时间。
文摘目的:探究NLR、LMR、PLR、D-D与接受免疫治疗的晚期非小细胞肺癌患者的无进展生存期的相关性。方法:回顾性分析接受免疫治疗的86例患者的临床资料,收集患者首次治疗前一周内的血常规及血清D-D,计算出NLR、LMR、PLR指标,根据RECIST1.1标准评价疗效并随访无进展生存期(progression-free survival, PFS),使用COX比例风险回归模型进行生存分析,筛选治疗前的基线参数中与疗效相关的指标。采用Kaplan⁃Meier法绘制生存曲线,用Log⁃rank检验比较组间生存率。探讨接受免疫治疗NSCLC患者PFS的影响因素。结果:通过预测非小细胞肺癌患者死亡率的ROC曲线分析确定,NLR最佳临界值为3.985,LMR最佳临界值为2.085,PLR最佳临界值为139.5,D-D最佳临界值为0.96。经过Log-rank检验得出单因素分析结果显示:性别、基因突变状态、器官转移个数、LMR、NLR、PLR及D-D是PFS的影响因素(p 0.05)。结论:在接受免疫治疗的NSCLC患者中,较低水平的NLR、PLR、D-D及较高水平的LMR患者与PFS更长相关,对其预后有一定的预测作用,基因突变状态、NLR、D-D是接受免疫治疗晚期NSCLC患者生存的独立预测因素。Objective: To explore the correlation between NLR, LMR, PLR, D-D and progression free survival in advanced non-small cell lung cancer patients receiving immunotherapy. Method: A retrospective analysis was conducted on the clinical data of 86 patients receiving immunotherapy. Blood routine and serum D-D were collected within one week before the first treatment, and NLR, LMR, and PLR indicators were calculated. The efficacy was evaluated according to the RECIST 1.1 standard and progression free survival (PFS) was followed up. The COX proportional hazards regression model was used for survival analysis, and indicators related to efficacy were screened from baseline parameters before treatment. Kaplan Meier method was used to plot survival curves, and Log rank test was used to compare survival rates between groups, exploring the influencing factors of PFS in NSCLC patients receiving immunotherapy. Result: Of ROC curve analysis for predicting the mortality rate of non-small cell lung cancer patients, the optimal critical values for NLR, LMR, PLR, and D-D were determined to be 3.985, 2.085, 139.5, and 0.96, respectively. After log rank testing, the results of univariate analysis showed that gender, gene mutation status, number of organ metastases, LMR, NLR, PLR, and D-D were the influencing factors of PFS (p 0.05). Conclusion: In NSCLC patients receiving immunotherapy, lower levels of NLR, PLR, D-D, and higher levels of LMR are associated with longer PFS and have a certain predictive effect on their prognosis. Gene mutation status, NLR, D-D are independent predictors of survival in advanced NSCLC patients receiving immunotherapy.
